Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

1. Accuracy of Self-report for Cervical and Breast Cancer Screening

Accuracy of Self-report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening Health Services Research & Development Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening to the ESP Report RSS feed Prepared by: Evidence Synthesis Program (ESP) Coordinating (...) Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Recommended Citation: Anderson J, Bourne D, Peterson, K, Mackey K. Evidence Brief: Accuracy of Self-report for Cervical and Breast Cancer Screening. VA ESP Project #09-199; 2019. Download PDF: , Purpose The ESP Coordinating Center (ESP CC) is responding to a request from the VHA Performance Workgroup for an evidence brief on the accuracy of patient self-report for cervical and breast cancer screening. Findings from

2019 Veterans Affairs Evidence-based Synthesis Program Reports

2. Universal Cervical Length Screening

Universal Cervical Length Screening No. 374-Universal Cervical Length Screening - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 41, Issue 3, Pages 363–374.e1 No. 374-Universal Cervical Length Screening x Kimberly Butt , MD Fredericton, NB x Joan Crane , MD St. Johns, NL x Jennifer Hutcheon , PhD Vancouver, BC x Ken Lim , MD Vancouver, BC x Ori Nevo , MD Toronto, ON No. 374, March 2019 DOI: To view the full text (...) , please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To review the evidence and provide an opinion as to whether universal cervical length screening to prevent preterm birth should be adopted across Canada. Outcomes Outcomes evaluated include prevention of preterm birth. Evidence Literature searches using Knowledge Finder, Medline and Cochrane databases were searched for articles published up to April 2018 on cervical length screening for prevention

2019 Society of Obstetricians and Gynaecologists of Canada

3. Screening for colorectal cancer-where does the fit-DNA test fit?

Screening for colorectal cancer-where does the fit-DNA test fit? Screening for Colorectal cancer-Where does the FIT-DNA test fit? – Clinical Correlations Search Screening for Colorectal cancer-Where does the FIT-DNA test fit? February 21, 2019 6 min read . Almost all CRC develops from precancerous polyps, and with appropriate colonoscopy screening most polyps can be detected and removed before they transform into cancer. Simply put, CRC screening saves lives. ; however, over 40% of . Perhaps (...) some of this resistance is due to the invasive nature of the mostcommon testing procedure, colonoscopy. Whatever the cause, this avoidance of testing has contributed to as many as . For many years, the USPTSF has recommended four different CRC screening modalities. Some are more invasive and off-putting than others. Colonoscopy, the gold standard, has the highest sensitivity and specificity for cancer detection but requires patients to forego solid food for a day and drink large volumes

2019 Clinical Correlations

4. Primary cervical screening with high risk human papillomavirus testing: observational study. (PubMed)

Primary cervical screening with high risk human papillomavirus testing: observational study. OBJECTIVE: To provide the first report on the main outcomes from the prevalence and incidence rounds of a large pilot of routine primary high risk human papillomavirus (hrHPV) testing in England, compared with contemporaneous primary liquid based cytology screening. DESIGN: Observational study. SETTING: The English Cervical Screening Programme. PARTICIPANTS: 578 547 women undergoing cervical screening (...) in primary care between May 2013 and December 2014, with follow-up until May 2017; 183 970 (32%) were screened with hrHPV testing. INTERVENTIONS: Routine cervical screening with hrHPV testing with liquid based cytology triage and two early recalls for women who were hrHPV positive and cytology negative, following the national screening age and interval recommendations. MAIN OUTCOME MEASURES: Frequency of referral for a colposcopy; adherence to early recall; and relative detection of cervical

2019 BMJ

5. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319b Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table (...) of Contents Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2019 AIM Specialty Health

6. New screening pathway could help to identify a rare, single-gene form of diabetes

New screening pathway could help to identify a rare, single-gene form of diabetes Signal - New screening pathway could help to identify a rare, single-gene form of diabetes Dissemination Centre Discover Portal NIHR DC Discover New screening pathway could help to identify a rare, single-gene form of diabetes Published on 23 January 2018 A screening pathway using blood and urine tests followed by two genetic (DNA) tests identified all people with a rare subtype of diabetes called monogenic (...) diabetes. The screening pathway performed better than current practice based on age at diagnosis and family history which misses 63%. It is, therefore, a useful approach for ruling out this form of diabetes and probably cheaper overall than offering every young person with diabetes DNA testing. Monogenic diabetes, caused by a mutation in a single gene can be misdiagnosed as type 1 diabetes, leading to unnecessary insulin treatment. Those recruited for this study were 98% white and tested at an average

2019 NIHR Dissemination Centre

7. Intensive management of diabetes detected early at screening shows similar results to standard care

Intensive management of diabetes detected early at screening shows similar results to standard care Signal - Intensive management of diabetes detected early at screening shows similar results to standard care Dissemination Centre Discover Portal NIHR DC Discover Intensive management of diabetes detected early at screening shows similar results to standard care Published on 1 November 2016 Intensive “early” treatment was similar to national guidance-based treatment at preventing diabetes-related (...) complications or heart disease over five years in this large trial. General practices in the UK (49 practices), Netherlands and Denmark screened 135,000 asymptomatic adults aged 40 to 69 for type 2 diabetes before offering one of two treatment approaches. Intensive management was geared towards achieving targets for blood glucose, blood pressure and cholesterol levels by providing support for GPs, and protected time for delivering extra monitoring, healthy lifestyle advice and medication. The comparison

2019 NIHR Dissemination Centre

8. Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women

Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Signal - Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Dissemination Centre Discover Portal NIHR DC Discover Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Published on 6 December 2016 Human Papilloma Virus (HPV) self-sampling kits and the opportunity to book appointments had (...) the largest effect in improving cervical screening uptake for those not responding to initial prompts. However, uptake improved only slightly from 27% to 30%, when the kit was sent. A survey of non-attenders showed they value the convenience and privacy of self-testing. This large NIHR trial tested a range of interventions to increase uptake among women eligible for their first cervical screening test. Sending information leaflets or giving online booking options before their first invitation had

2019 NIHR Dissemination Centre

9. Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation

Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Signal - Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 General practice software that generated screen reminders for patients with atrial fibrillation did not increase the proportion taking oral (...) it is important to understand why some patients are not taking preventative medicines. This study addressed this challenge by testing software that generated screen reminders when atrial fibrillation patients were seen in general practice. What did this study do? This cluster-randomised controlled trial assigned 47 general practices in England to either usual practice or to a new proprietary software tool – Automated Risk Assessment for Stroke in Atrial Fibrillation. The software generated screen reminders

2019 NIHR Dissemination Centre

10. Financial incentives do not increase attendance for diabetic eye screening

Financial incentives do not increase attendance for diabetic eye screening Signal - Financial incentives do not increase attendance for diabetic eye screening Dissemination Centre Discover Portal NIHR DC Discover Financial incentives do not increase attendance for diabetic eye screening Published on 11 July 2017 Two types of financial incentives are not effective at increasing attendance at eye screening for people with diabetes who do not regularly attend screening. Surprisingly, financial (...) incentives may even reduce the numbers of people attending screening. Retinopathy is a type of eye disease common to people with diabetes. Sight deteriorates only in the later stages and early diagnosis and treatment can prevent blindness. Annual eye screening is offered for people with diabetes but take-up could be improved. This trial examined the effectiveness of a small fixed fee incentive and a lottery incentive compared to an invitation letter. Contrary to expectation the financial incentives were

2019 NIHR Dissemination Centre

11. Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources

Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources Abdominal aortic aneurysm screening for women not cost effective Dissemination Centre Discover Portal NIHR DC Discover Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources Published on 13 November 2018 doi: Nearly 4,000 women would need screening to prevent one death, and a third of aneurysms detected wouldn’t have influenced the individual woman's health (...) or lifespan. Aneurysm rupture is a life-threatening emergency with low survival. Men are known to be at higher risk of an aneurysm and are offered screening at age 65 to allow early diagnosis of aneurysms large enough to warrant surgical repair. However, a third of deaths from rupture are in women. This NIHR-funded study is the first to model the potential benefits, harms and cost-effectiveness of abdominal aortic aneurysm screening in women. All screening scenarios were estimated to exceed the NHS cost

2019 NIHR Dissemination Centre

12. Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. (PubMed)

Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. Background: In 2016, universal individual donation nucleic acid testing (ID-NAT) of donated blood for Zika virus began in U.S. states and territories. Objective: To assess the cost-effectiveness of universal ID-NAT in the first year of screening compared with alternatives for the 50 states and separately for Puerto Rico. Design: Microsimulation that captured Zika-related harms (...) strategies in the 50 states were also considered. Outcome Measures: Costs, quality-adjusted life-years (QALYs), and outcomes. Results of Base-Case Analysis: In Puerto Rico, MP-NAT exclusively during high mosquito season was cost-effective at $81 123 per QALY (95% CI, -$49 138 to $978 242 per QALY). No screening policy was cost-effective in the 50 states. Universal ID-NAT cost $341 million per QALY (CI, $125 million to $2.90 billion per QALY) compared with no screening in the 50 states. Results

2019 Annals of Internal Medicine

13. Avioq htlv-i/ii microelisa system - for use in screening individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II, and for use as an aid in clinical diagnosis

Avioq htlv-i/ii microelisa system - for use in screening individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II, and for use as an aid in clinical diagnosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary Basis

2019 Health Canada - Drug and Health Product Register

14. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA www.ecdc.europa.euECDC SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA ii This report from the European Centre for Disease Prevention and Control (ECDC (...) Prevention and Control. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Stockholm: ECDC; 2018. Stockholm, November 2018 ISBN 978-92-9498-280-3 doi: 10.2900/154411 Catalogue number TQ-04-18-919-EN-N © European Centre for Disease Prevention and Control, 2018 Reproduction is authorised, provided the source is acknowledged. SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived

2019 European Centre for Disease Prevention and Control - Public Health Guidance

15. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up 30420254 2018 11 13 1873-7560 2018 Nov 09 European urology Eur. Urol. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. S0302-2838(18)30851-0 10.1016/j.eururo.2018.10.053 We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 (...) basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11

2019 EvidenceUpdates

16. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

2018 Canadian Task Force on Preventive Health Care

17. Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke

Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke 30354974 2018 10 25 1524-4628 49 9 2018 Sep Stroke Stroke Emergent Large Vessel Occlusion Screen Is an Ideal Prehospital Scale to Avoid Missing Endovascular Therapy in Acute Stroke. 2096-2101 10.1161/STROKEAHA.118.022107 Background and Purpose- The strong evidence of endovascular therapy in acute ischemic stroke patients with large vessel occlusion (LVO) is revealed (...) . Such patients are required to direct transport to the hospital capable of endovascular therapy. There are several prehospital scales available for paramedics to predict LVO. However, they are time consuming, and several of them include factors caused by other types than LVO. Therefore, we need a fast, simple, and reliable prehospital scale for LVO. Methods- We developed a new prehospital stroke scale, emergent large vessel occlusion (ELVO) screen, for paramedics to predict LVO. The study was prospectively

2018 EvidenceUpdates

18. Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening

Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening Final Update Summary: Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: Screening Release Date: October 2018 Recommendation Summary Population (...) Recommendation Grade Women of reproductive age The USPSTF recommends that clinicians screen for intimate partner violence (IPV) in women of reproductive age and provide or refer women who screen positive to ongoing support services. See the for more information on effective ongoing support services for IPV and for information on IPV in men. Older or vulnerable adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for abuse and neglect

2018 U.S. Preventive Services Task Force

19. Screening for Colorectal Cancer

Screening for Colorectal Cancer CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus Desmond Leddin, 1,2, * David A. Lieberman, 3, * Frances Tse, 4 Alan N. Barkun, 5 Ahmed M. Abou-Setta, 6 John K. Marshall, 4 N. Jewel Samadder, 7 Harminder Singh, 6,8 Jennifer J. Telford, 9 Jill Tinmouth, 10 Anna N. Wilkinson, 11 (...) Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada BACKGROUND & AIMS: A family history (FH) of colorectal cancer (CRC) increases the risk of developing CRC. These consensus recommendations developed by the Canadian As- sociation of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on screening these high-risk individuals. METHODS: Multiple parallel systematic review streams, informed by 10 literature searches, assembled

2018 Canadian Association of Gastroenterology

20. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation

Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose CT screening may be effective in reducing lung cancer mortality, but there is considerable uncertainty around effectiveness and value. {{author}} {{($index , , , , , , & . Tristan Snowsill 1, * , Huiqin Yang 1 , Ed Griffin 1 , Linda Long 1 , Jo Varley-Campbell 1 , Helen Coelho 1 , Sophie Robinson 1 , Chris Hyde 1, 2 1 Peninsula Technology Assessment

2018 NIHR HTA programme